Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definition
1.2 Base estimates & calculations
1.3 Data validation
1.4 Forecast parameters
1.5 Data sources
1.5.1 Primary
1.5.2 Secondary
1.5.2.1 Paid sources
1.5.2.2 Unpaid sources
Chapter 2 Executive Summary
2.1 Industry 360° synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Growing geriatric population
3.2.1.2 Increasing prevalence of leukemia
3.2.1.3 Increased research and development actitives related to hairy cell leukemia
3.2.2 Industry pitfalls & challenges
3.2.2.1 Limited disease awareness
3.2.2.2 High-cost associated with treatment
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Porter's analysis
3.5.1 Supplier power
3.5.2 Buyer power
3.5.3 Threat of new entrants
3.5.4 Threat of substitutes
3.5.5 Industry rivalry
3.6 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company matrix analysis
4.3 Company market share analysis
4.4 Competitive positioning matrix
4.5 Strategic dashboard
Chapter 5 Market Estimates and Forecast, By Therapy, 2018 – 2032 ($ Mn)
5.1 Key trends
5.2 Chemotherapy
5.3 Targeted therapy
5.4 Immunotherapy
5.5 Surgery
Chapter 6 Market Estimates and Forecast, By Gender, 2018 – 2032 ($ Mn)
6.1 Key trends
6.2 Male
6.3 Female
Chapter 7 Market Estimates and Forecast, By Treatment Provider, 2018 – 2032 ($ Mn)
7.1 Key trends
7.2 Hospitals & clinics
7.3 Cancer care centers
7.4 Academic and research institutes
Chapter 8 Market Estimates and Forecast, By Region, 2018 – 2032 ($ Mn)
8.1 Key trends
8.2 North America
8.2.1 U.S.
8.2.2 Canada
8.3 Europe
8.3.1 Germany
8.3.2 UK
8.3.3 France
8.3.4 Spain
8.3.5 Italy
8.3.6 Rest of Europe
8.4 Asia Pacific
8.4.1 China
8.4.2 Japan
8.4.3 India
8.4.4 Australia
8.4.5 Rest of Asia Pacific
8.5 Latin America
8.5.1 Brazil
8.5.2 Mexico
8.5.3 Rest of Latin America
8.6 Middle East and Africa
8.6.1 South Africa
8.6.2 Saudi Arabia
8.6.3 Rest of Middle East and Africa
Chapter 9 Company Profiles
9.1 Amgen Inc.
9.2 Astellas Pharma Inc.
9.3 AstraZeneca plc
9.4 F. Hoffmann-La Roche Ltd.
9.5 Gilead Sciences, Inc.
9.6 Johnson & Johnson
9.7 Merck KGaA
9.8 Novartis AG
9.9 Pfizer Inc.
9.10 Takeda Pharmaceutical Company Limited
